NCT00573391 · OUTCOME

Participant Survival With Velcade/Melphalan/Dexamethasone Treatment vs. Participant Survival With Velcade/Thalidomide/Dexamethasone Treatment

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2 · Source last updated 2011-08-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: Participant
Interval / dispersion: Not reported
Time frame: 24 months

What was measured

due to low accrual rates, no analyses was done to compare the new combination of Velcade/Melphalan/Dexamethasone vs. Velcade/Thalidomide/Dexamethasone

Groups in this outcome

Velcade, Thalidomide, and Dexamethasone

Velcade 1.0 mg/m\^2 Velcade 1.3 mg/m\^2 D1,4, 8, 11 (x 6 cycles, then 1.0 mg/m\^2 (for cycles 7-12) Thalidomide 100 mg D1-28 Dexamethasone 20 mg D1-4 and 8-11

VMD With Melphalan Dose Escalation

VMD: Velcade 1.3 mg/m\^2 D1, 4, 7, 10 (x6 mo, then 1.0 mg/m\^2) Melphalan 4 (6, 8, 10) mg/m\^2 D1, 4, 7, 10 dose escalation Dexamethasone 20 mg 1-4 and 7-10

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Velcade, Thalidomide, and Dexamethasone	0
VMD With Melphalan Dose Escalation	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
group Id
OG001
value
0
units
Participants

description

due to low accrual rates, no analyses was done to compare the new combination of Velcade/Melphalan/Dexamethasone vs. Velcade/Thalidomide/Dexamethasone

groups

description
Velcade 1.0 mg/m\^2 Velcade 1.3 mg/m\^2 D1,4, 8, 11 (x 6 cycles, then 1.0 mg/m\^2 (for cycles 7-12) Thalidomide 100 mg D1-28 Dexamethasone 20 mg D1-4 and 8-11
id
OG000
title
Velcade, Thalidomide, and Dexamethasone
description
VMD: Velcade 1.3 mg/m\^2 D1, 4, 7, 10 (x6 mo, then 1.0 mg/m\^2) Melphalan 4 (6, 8, 10) mg/m\^2 D1, 4, 7, 10 dose escalation Dexamethasone 20 mg 1-4 and 7-10
id
OG001
title
VMD With Melphalan Dose Escalation

param Type

NUMBER

reporting Status

POSTED

time Frame

24 months

title

Participant Survival With Velcade/Melphalan/Dexamethasone Treatment vs. Participant Survival With Velcade/Thalidomide/Dexamethasone Treatment

type

PRIMARY

unit Of Measure

Participant

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice